Primary brain amyloidoma, both a neoplastic and a neurodegenerative disease: a case report

Mario Löhr1*, Almuth F. Kessler1, Camelia-Maria Monoranu2, Jens Grosche3, Thomas Linsenmann1, Ralf-Ingo Ernestus1 and Wolfgang Härtig3

Abstract

Background: Scattered extracellular deposits of amyloid within the brain parenchyma can be found in a heterogeneous group of diseases. Its condensed accumulation in the white matter without evidence for systemic amyloidosis is known as primary brain amyloidoma (PBA). Although originally considered as a tumor-like lesion by its space-occupying effect, this condition displays also common hallmarks of a neurodegenerative disorder.

Case presentation: A 50-year-old woman presented with a mild cognitive decline and seizures with a right temporal, irregular and contrast-enhancing mass on magnetic resonance imaging. Suspecting a high-grade glioma, the firm tumor was subtotally resected. Neuropathological examination showed no glioma, but distinct features of a neurodegenerative disorder. The lesion was composed of amyloid AL aggregating within the brain parenchyma as well as the adjacent vessels, partially obstructing the vascular lumina. Immunostaining confirmed a distinct perivascular inflammatory reaction. After removal of the PBA, mnestic impairments improved considerably, the clinical course and MRI-results are stable in the 8-year follow-up.

Conclusion: Based on our histopathological findings, we propose to regard the clinicopathological entity of PBA as an overlap between a neoplastic and neurodegenerative disorder. Since the lesions are locally restricted, they might be amenable to surgery with the prospect of a definite cure.

Keywords: Amyloidoma, Neurooncology, Brain tumor, Neurodegenerative disease, Neurovascular unit

Background

Primary brain amyloidoma (PBA) is a rare tumor-like lesion characterized by a condensed deposition of amyloid within the brain parenchyma without evidence for systemic amyloidosis. PBA was originally reported by Saltykow in 1935 [1] followed by almost 40 additional cases with an average age of the patients at diagnosis of 49 (15–71) years [2]. However, the actual incidence of the condition is unknown. In almost all cases, the amyloid accumulations were found exclusively in the white matter of different supratentorial brain regions, predominantly in the frontal lobe and in proximity to the ventricular system [3, 4]. As neuroimaging features are multifaceted - except the disruption of the blood-brain-barrier (BBB) as the solely consistent finding - PBA was denominated a “chameleon-like lesion” due to the mimicking of different brain pathologies [3]. Apart from their neoplastic phenotype, as a slowly growing mass lesion, PBA's are part of a complex group of progressive neurodegenerative disorders associated with an extracellular accumulation of fibrillar amyloid aggregates including, e.g., congophilic angiopathy and Alzheimer’s disease. Although composed of different precursor molecules, all cerebral amyloid deposition disorders entail common clinical symptoms, i.e., cognitive deficits, dementia, seizures, stroke, focal neurological signs, or a combination thereof [4].
Case presentation
This 50-year-old female patient complained of a slow decline of her cognitive speed over several months and became symptomatic with generalized seizures. Her previous history revealed a myocardial infarction at the age of 42 years. Computerized tomography (CT) and magnetic resonance imaging (MRI) of the head showed a right temporal mass with focal calcifications, moderate perifocal edema and a reticulated contrast enhancement comprising neo- and allocortical regions (Fig. 1). Suspecting a high-grade glioma with an oligodendroglial component, the tumor was resected subtotally. Unexpectedly, the intraoperative finding was a firm, partially calcified and pink to greyish mass that was hypovascularized and poorly demarcated, so that no clear resection border could be defined intraoperatively.

Postoperatively, the patient recovered well, displayed a gradual cognitive improvement during the 24-month follow-up. She kept seizure-free under antiepileptic medication to date during the 8-year follow-up. MRI did not show any recurrence so far.

Neuropathological findings
Neuropathological examination showed no evidence of a glioma, but instead neuroectodermal tissue interspersed with scattered accumulations of periodic acid-Schiff (PAS)-positive, amorphous material located in the extracellular space that showed a distinct association to blood vessels where it assembled in a shell-like fashion. Congo Red staining clearly visualized extracellular amyloid deposits displaying apple-green birefringence under polarized light (Fig. 2a). Immunohistochemical analysis revealed aggregated λ-light chain (AL) amyloid with thioflavin S-stained β-pleated sheet conformation (Fig. 3A to A’’). In addition to the space-occupying effect of the widespread extracellular amyloid deposits, a marked dissociation of the vessel walls with subsequent stenosis (Fig. 1a) and even total obstruction of the vascular lumina became apparent (Fig. 3B to B’’). Furthermore, the lesion was characterized by a distinct perivascular inflammatory reaction comprising of macrophages (Fig. 2b), microglia and T-lymphocytes (Fig. 2c), but also scattered B-lymphocytes and plasma cells (Fig. 2d). Despite the transmural inflammation and

Fig. 1 Neuroradiologic imaging pattern of primary brain amyloidoma. The T1-weighted MRI sequence shows a slightly hypointense right temporal mass (arrows in a), an ill-defined, moderate gadolinium enhancement (arrows in b), both compatible with malignant glioma. The CT displays small focal calcifications (arrows in c). The corresponding T2- and FLAIR MRI sequences displayed a hyperintense signal extending beyond the margins of the contrast enhancement indicating peritumoral edema or an infiltrating part of the mass (arrows in d and e). Almost 2 years following surgical removal of the PBA, the T1-weighted MRI sequence shows contrast enhancement at the resection margins (arrows in f), compatible with residual amyloidoma that remained unchanged during the 8-year follow-up.
extensive amyloid deposition, there was no evidence of a resulting vessel fragility, since intraparenchymal hemorrhage was virtually absent (Fig. 2e). After identification of the tumor mass as a cerebral amyloidoma, systemic workup including rectal biopsy with negative results after Congo Red staining and echocardiography revealed no findings suspect for systemic amyloidosis, thus confirming the diagnosis of a PBA.

Discussion and conclusions
PBA intriguingly share unequivocal features of two traditionally different nosological entities, i.e. cerebral neoplastic and neurodegenerative disorders. The localized aggregation of the amyloid in PBA suggests a synthesis of the insoluble protein at the site of the deposition rather than its leakage from the vessels [5]. As the amyloid of the cases reported almost exclusively was found to be of the light chain (AL) \( \lambda \) type, and in situ hybridization of scattered plasma cells squeezed between cerebral amyloid masses had shown a massive preponderance of \( \lambda \) producing cells, the concept to regard PBA as a low-grade monoclonal B-cell neoplasm capable of terminal differentiation had been proposed by Laeng et al. [6], but was later questioned by others [7, 8]. However, the main reason assigning PBA to cerebral neoplastic disorders is its progressive space-occupying effect, in combination with a disrupted BBB mimicong high-grade glioma [9], but rendering the lesions accessible for surgical treatment with a benign course thereafter [2, 3, 10]. As yet, there is only one report on a small recurrent lesion 15 years after complete excision [5].
Although PBA may be multiple and of variable sizes at presentation, the aggregates were always locally constricted and no dissemination within the brain was described so far, neither radiologically nor in necropsy cases [2, 5, 6, 11, 12]. Aside from PBA, brain-restricted light chain (AL) amyloid deposition is found in some different rare entities, presenting as single or multiple solid masses in solitary intracerebral plasmacytoma and primary intracerebral lymphoma with plasmacytic differentiation, and as disseminated lesions in multiple sclerosis with demyelination-associated amyloid aggregates, leptomeningeal vascular amyloidosis, and widespread subcortical vascular amyloidosis [4, 13, 14]. Since cerebral amyloid deposits can be associated with systemic amyloidosis, this has to be ruled by a thorough diagnostic workup [15, 16].

The main pathomorphological finding that underlines the neurodegenerative character of PBA are the vast peri- and intravascular amyloid deposits occurring in vessels adjacent to the parenchymal amyloid masses, probably reflecting a vascular clearance pathway of the neurotoxic amyloid by an active transport of the protein from the adventitial to the luminal side [5, 17]. In contrast to sporadic cerebral amyloid angiopathy (CAA), where the amyloid-ß deposits in the media and adventitia of cortical and leptomeningeal vessels lead to vascular fragility and rupture [18], the amyloid accumulations in PBA, though extensive, do not seem to increase the risk for intracerebral bleeding, since (micro)hemorrhages were virtually absent in the present case and are also not reported in the literature so far.

Due to the obstruction of parenchymal arterioles in PBA, local cerebral blood flow and the brain’s trophic support are severely impaired, disturbing BBB function and further aggravating the already diminished clearance mechanisms for the elimination of the insoluble protein aggregates [19, 20]. The perivascular space in PBA also houses a plethora of immune cells. Among the amyloid-induced perivascular inflammatory infiltrate [4], the abundant perivascular macrophages (PVMs) may act as scavenger cells to counteract the accumulation of amyloid that has been demonstrated in models of cerebral amyloid angiopathy [21]. Moreover, PVMs are a major source of reactive oxygen species. In animal models of Aß overproduction, the vascular oxidative stress by PVMs has been identified as a key effector for neurovascular and the ensuing cognitive dysfunction [22].

The final result of these self-amplifying effects is an enduring disturbance of the neurovascular unit in brain...
areas affected by AL-amyloid. Thus, a vicious circle of hypoxic/ischemic and neurodegenerative pathology arises, accelerated by the perivascular inflammation. This coexistence and mutual amplification of neurovascular dysfunction, inflammation and oxidative stress is detrimental to neuronal function and entails cognitive decline and focal neurological signs, as demonstrated for several forms of cerebral amyloidosis [4].

The histopathological findings of our case support the hypothesis, that PBA is a rare but unique clinicopathologic entity as it comprises distinct features of both, neoplastic and neurodegenerative disorders. Since the lesions are locally restricted and might be amenable to surgery, PBA has a prospect of definite cure in contrast to most other cerebral amyloid disorders.

Abbreviations

AL: Amyloid light chain; BBB: Blood-brain-barrier; CAA: Cerebral amyloid angiopathy; CT: Computedized tomography; MRI: Magnetic resonance imaging; PBA: Primary brain amyloidoma; PVMs: Perivascular macrophages

Acknowledgements

This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Access Publishing.

Funding

None.

Availability of data and materials

All data and material supporting the conclusions of this article is included in the article.

Authors’ contributions

ML and RIE developed the concept and design of the underlying study. CMM and WH performed tissue preparation and immunohistochemical staining, and JG elaborated the laser scanning microscopy. ML, TL, WH and AFK analysed and interpreted the data. ML and TL drafted the manuscript, followed by a critical revision and intellectual contributions by JG, AFK, CMM and RIE. WH gave the final approval of the version to be published. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Informed consent for participation was obtained from the patient.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying images. Although she had noticed a slight impairment of cognitive speed in her academic profession, neither her reasoning nor her judgement faculties were affected as assessed by the attending neurologists preoperatively. A copy of the written consent is available for review by the editor of BMC Neurology.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Neurosurgery, University Hospital of Wuerzburg, Josef-Schneider-Str. 11, 97080 Wurburg, Germany. 2Department of Neuropathology, Institute of Pathology, University of Wuerzburg, Josef-Schneider-Str. 2, 97080 Wurburg, Germany. 3Paul Fleischig Institute for Brain Research, University of Leipzig, Liebigstr. 19, 04103 Leipzig, Germany.

Received: 25 July 2018 Accepted: 18 March 2019

References

1. Salykow S. Zur Frage des lokalen Amyloids der Hirngefäße. Virchows Arch. 1935;296:590.
2. Hell K, Poznanski J, Hegenbart U, Brokinkel B, Berndt R, Keyhani K, et al. Cerebral amyloidoma is characterized by B-cell clonality and a stable clinical course. Brain Pathol. 2018;28:234–9.
3. Fischer B, Palkovic S, Rickert C, Weckesser M, Wassmann HD. Cerebral AL-λ amyloidoma: clinical and pathomorphological characteristics. Review of the literature and of a patient. Amyloid. 2007;14:11–9.
4. Rostagno A, Holton JL, Lashley T, Revesz T, Ghiso J. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci. 2010;67:581–600.
5. Westmark P. Localized AL amyloidosis: a suicidal neoplasm? Ups J Med Sci. 2012;117(2):244–50.
6. Laeng RH, Altematt HU, Scheithauer BW, Zimmermann DR. Amyloidomas of the nervous system. A monoclonal B-cell disorder with monotypic amyloid light chain λ amyloid production. Cancer. 1998;82:362–74.
7. Foreid H, Barroso C, Evangelista T, Campos A, Pimentel J. Intracerebral amyloidoma: case report and review of the literature. Clin Neuropathol. 2010;29:217–22.
8. Tabatabai G, Baehring J, Hochberg FH. Primary amyloidoma of the brain parenchyma. Arch Neurol. 2005;62:677–80.
9. Ragel BT, Blumenschel DT, Baud W, Salzman KL, Jensen RL. Intracerebral amyloidoma can mimic high-grade glioma on magnetic resonance imaging and spectroscopy. Arch Neurol. 2006;63:906–7.
10. Renard D, Campello C, Rigau V, de Champfleur N, Labauge P. Primary brain amyloidoma. Long-term follow-up. Arch Neurol. 2008;65:979–80.
11. Hori A, Kitanomo T, Tateishi J, Hann P, Friede RL. Focal intracerebral accumulation of a novel type of amyloid protein An early stage of cerebral amyloidosis? Acta Neuropathol. 1988;76:212–5.
12. Townsend JJ, Tomiyasu U, MacKay A, Wilson CB. Central nervous system amyloid presenting as a mass lesion. J Neurol. 1982:5:439–42.
13. Schröder R, Deckert M, Linke RP. Novel isolated cerebral AL-λ amyloid angiopathy with widespread subcortical distribution and leukoencephalopathy due to atypical mononodal plasma cell proliferation, and terminal systemic gammopathy. J Neuropathol Exp Neurol. 2009;68:286–99.
14. Pace AA, Lownes SE, Shianne A, Hilton DA, Weatherby SJ. A tale of the unexpected: amyloidoma associated with intracerebral lymphoplasmacytic angiopathy. J Neuropathol Exp Neurol. 2005;64:208–19.
15. Wechalekar AD, Gilmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54.
16. Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017;96:17–42.
17. Schwab S, Hegerl U, Barres BA. Neuronal activity regulates regenerative angiogenesis in the adult brain. Nature. 2007;449:381–6.
18. Resink TJ, van der Zee AGC, Wijers MA, van den Berghe H, van der Voort RHJ, van der Loo DD. Peroxidase and plasma membrane localization of the mannose-6-phosphate receptor in HepG2 cells. J Biol Chem. 1998;273:9–16.
19. Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl Acad Sci U S A. 2009;106:1261–6.
20. Park L, Uekawa K, Garcia-Bonilla L, Kolzumi K, Murphy M, Pitstick R, et al. Brain perivascular macrophages initiate the neurovascular dysfunction of Alzheimer Aβ peptides. Circ Res. 2017;121:258–69.